Market
Story
FDA Approves January 26, 2025, Monthly Maintenance Dosing for Eisai/Biogen's lecanemab-irmb in Early Alzheimer's Treatment
Jan 27, 2025, 02:46 AM
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease. This decision, announced on January 26, 2025, allows for intravenous administration of the drug developed by Eisai Co. Ltd. and Biogen. The approval signals a significant advancement in the treatment options available for early-stage Alzheimer's patients, providing a new avenue for ongoing management of the disease.
View original story
Similar markets
Less than 20 • 25%
20 to 30 • 25%
31 to 40 • 25%
More than 40 • 25%
0-1 new treatments • 25%
4-5 new treatments • 25%
2-3 new treatments • 25%
More than 5 new treatments • 25%
No • 50%
Yes • 50%
China • 25%
Other • 25%
European Union • 25%
United States • 25%
1-4 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
5-9 countries • 25%
Less than 5 • 25%
11 to 15 • 25%
More than 15 • 25%
5 to 10 • 25%
Other • 25%
FDA (United States) • 25%
EMA (European Union) • 25%
PMDA (Japan) • 25%
0-5 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
6-10 countries • 25%
Less than 50 • 25%
More than 120 • 25%
50 to 80 • 25%
81 to 120 • 25%
10 to 20 • 25%
Less than 10 • 25%
21 to 30 • 25%
More than 30 • 25%
More than 15 • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 30 countries • 25%
Less than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%